Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been many oncology drug approvals. Over time, the number of approvals decreased each year.
Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been good number of oncology drug approvals. Over time, number of approvals each year have dropped down from 22, to 19 and so on.
As of 2023, there's only been two drugs approved, Tancredi sees that "there could be three or four drugs approved before the end of this year, maybe more." There's a number of products in the pipeline that could get approved this year.
"So when it's all said and done at the end of 2023, you know, we could be in double digits again, for as far as approvals are concerned," he added.
FDA Sets Review Date for Datopotamab Deruxtecan in Breast Cancer
April 2nd 2024Datopotamab deruxtecan, which is being reviewed to treat adults with HR-positive, HER2-negative breast cancer, has an FDA target date in the first quarter of 2025. Datopotamab deruxtecan also is under FDA review for non-small cell lung cancer.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More